The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.: A consensus document of the Italian Federation of Thrombosis Centers (FCSA)
Abstract
Summary: Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Mant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
Medication Adherence: Its Importance in Cardiovascular Outcomes
Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. (2009) · Circulation · doi:10.1161/circulationaha.108.768986 · Cited by 1,488
Cited by
Roldán, V., Marín, F., Fernández, H., Manzano-Fernández, S., Gallego, P., Valdés, M., Vicente, V., & Lip, G. Y. H. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.045 · Cited by 117
Metadata
- Authors
- Crippa, L., Falanga, A., Finazzi, G., Marongiu, F., Palareti, G., Poli, D., Testa, S., Tiraferri, E., Tosetto, A., Tripodi, A., Manotti, C., & Pengo, V.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2011
- Volume
- 106
- Issue
- 11
- Pages
- 868-876
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W1820675324
- Cited by
- 159
- References
- 4
- FWCI
- 23.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.: A consensus document of the Italian Federation of Thrombosis Centers (FCSA). https://app.cochat.ai/papers/10.1160/th11-05-0358
- The paper
- Crippa, L., Falanga, A., Finazzi, G., Marongiu, F., Palareti, G., Poli, D., Testa, S., Tiraferri, E., Tosetto, A., Tripodi, A., Manotti, C., & Pengo, V. (2011). Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.: A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thrombosis and Haemostasis. https://doi.org/10.1160/th11-05-0358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
